LENZ Therapeutics Inc (LENZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has a cash flow conversion efficiency ratio of -0.116x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.02 Million) by net assets ($284.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LENZ Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how LENZ Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LENZ liabilities breakdown for a breakdown of total debt and financial obligations.
LENZ Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LENZ Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Chlor-Alkali Chemical Co Ltd B
SHG:900908
|
0.015x |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
0.088x |
|
STIF Société anonyme
PA:ALSTI
|
-0.068x |
|
H+H International A/S
CO:HH
|
0.100x |
|
MEDI ASSIST HEALTHCARE SERVICES LIMITED
NSE:MEDIASSIST
|
0.026x |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
0.029x |
|
Wiz Soluções e Corretagem de Seguros S.A
SA:WIZC3
|
0.106x |
|
Beyond Meat Inc
NASDAQ:BYND
|
-0.834x |
Annual Cash Flow Conversion Efficiency for LENZ Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of LENZ Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see LENZ Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $284.34 Million | $-69.17 Million | -0.243x | +16.41% |
| 2024-12-31 | $204.08 Million | $-59.39 Million | -0.291x | -144.68% |
| 2023-12-31 | $-92.71 Million | $-60.38 Million | 0.651x | -82.11% |
| 2022-12-31 | $-24.17 Million | $-87.98 Million | 3.640x | -2.10% |
| 2021-12-31 | $-14.21 Million | $-52.85 Million | 3.718x | +317.84% |
| 2020-12-31 | $-9.80 Million | $-8.72 Million | 0.890x | +10288.39% |
| 2019-12-31 | $-2.22 Million | $-19.00K | 0.009x | -- |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more